A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier is disclosed comprising the step of determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs), identifying the subject as a predicted responder or non-responder to glatiramer acetate based on the determined SNP genotype, and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
